Suppr超能文献

非酒精性脂肪性肝炎:综述。

Nonalcoholic Steatohepatitis: A Review.

机构信息

Department of Surgery, University of Minnesota, Minneapolis.

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.

出版信息

JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.

Abstract

IMPORTANCE

Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant. Despite its importance, NASH is underrecognized in clinical practice.

OBSERVATIONS

NASH affects an estimated 3% to 6% of the US population and the prevalence is increasing. NASH is strongly associated with obesity, dyslipidemia, type 2 diabetes, and metabolic syndrome. Although a number of noninvasive tests and scoring systems exist to characterize NAFLD and NASH, liver biopsy is the only accepted method for diagnosis of NASH. Currently, no NASH-specific therapies are approved by the US Food and Drug Administration. Lifestyle modification is the mainstay of treatment, including dietary changes and exercise, with the primary goal being weight loss. Substantial improvement in histologic outcomes, including fibrosis, is directly correlated with increasing weight loss. In some cases, bariatric surgery may be indicated to achieve and maintain the necessary degree of weight loss required for therapeutic effect. An estimated 20% of patients with NASH will develop cirrhosis, and NASH is predicted to become the leading indication for liver transplants in the US. The mortality rate among patients with NASH is substantially higher than the general population or patients without this inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per 1000 person-years and a liver-specific mortality rate of 11.77 per 1000 person-years.

CONCLUSIONS AND RELEVANCE

Nonalcoholic steatohepatitis affects 3% to 6% of the US population, is more prevalent in patients with metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associated with increased rates of liver-specific and overall mortality. Early identification and targeted treatment of patients with nonalcoholic steatohepatitis are needed to improve patient outcomes, including directing patients toward intensive lifestyle modification to promote weight loss and referral for bariatric surgery as indicated for management of obesity and metabolic disease.

摘要

重要性

非酒精性脂肪性肝炎(NASH)是非酒精性脂肪性肝病(NAFLD)的炎症亚型,与疾病进展、肝硬化发展和肝移植需求相关。尽管其重要性,NASH 在临床实践中仍未得到充分认识。

观察结果

NASH 估计影响美国人口的 3%至 6%,且患病率正在增加。NASH 与肥胖、血脂异常、2 型糖尿病和代谢综合征密切相关。尽管有许多非侵入性的测试和评分系统存在来描述 NAFLD 和 NASH,但肝活检是诊断 NASH 的唯一被接受的方法。目前,美国食品和药物管理局尚未批准任何专门用于治疗 NASH 的药物。生活方式的改变是治疗的主要方法,包括饮食改变和运动,主要目标是减肥。组织学结果的显著改善,包括纤维化,与体重减轻的增加直接相关。在某些情况下,可能需要进行减肥手术来达到并维持治疗效果所需的必要减肥程度。估计有 20%的 NASH 患者会发展为肝硬化,NASH 预计将成为美国肝移植的主要指征。NASH 患者的死亡率明显高于一般人群或没有这种非酒精性脂肪性肝炎炎症亚型的患者,年全因死亡率为 25.56/1000 人年,肝特异性死亡率为 11.77/1000 人年。

结论和相关性

非酒精性脂肪性肝炎影响美国人口的 3%至 6%,在代谢疾病和肥胖患者中更为普遍,约 20%的病例进展为肝硬化,并与肝特异性和总体死亡率的增加相关。需要早期识别和针对性治疗非酒精性脂肪性肝炎患者,以改善患者的预后,包括指导患者进行强化生活方式改变以促进减肥,并根据肥胖和代谢疾病的管理情况转介减肥手术。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验